remedium bio

Remedium is a biotechnology company focused on the development of treatments for large unmet clinical needs. To enable this, we developed a revolutionary gene therapy platform, which enables safe, effective, and durable delivery of therapeutic genes while allowing for simple post-treatment dose adjustment. The Prometheus™ adjustable gene therapy platform enables replacement of a broad range of subcutaneously administered protein treatments with a single injection, adjustable dose gene therapy. The system has an exceptionally high degree of specificity and remains localized to the site of the subcutaneous injection, offering a safe and durable, single injection alternative, at a fraction of the current protein-based therapeutic treatment cost. Remedium’s pipeline includes several disease modifying treatments with unprecedented efficacy in the fields of endocrinology (weight loss and type 2 diabetes), immunology, neurology, and musculoskeletal diseases.

Modalities and Indications

  • Gene Therapy
    Vehicle and Cargo

    As an extension of biotechnology, gene therapy is an advanced therapeutic modality with the promise of durable cures for a broad range of diseases. At its most basic level, gene therapy is comprised of a delivery vector or vehicle and therapeutic genetic cargo, which encodes the treatment gene. Remedium utilizes two of the most well characterized and established vectors, proven safe and effective in a broad range of patients and therapeutic indications – the adeno associated virus (AAV) and lipid nanoparticles (LNP). We select and optimize vectors based on disease indication, target tissues, and therapeutic transgene - optimizing safety, efficacy, and durability of expression.

  • Endocrinology
    Weight Loss and Type 2 Diabetes

    Obesity and Type 2 diabetes (T2D) are reaching pandemic proportions. Comprising roughly 90% of all Diabetes cases, and affecting nearly 500 million patients around the globe, Type 2 Diabetes (T2D) is a highly debilitating condition characterized by Beta-cell insufficiency and insulin resistance. Long term complications of obesity and T2D include heart disease, stroke, blindness, and kidney failure, with many patients requiring amputation due to inability to control the disease or manage complications. While a number of treatment options are available, the disease prevalence continues to rise and persistent reversal of disease progression is rarely achieved. Remedium is developing a first-in-class, single injection gene therapy for the treatment of Obesity and T2D with potentially improved safety and efficacy profiles over current gold standard treatments.

  • Neurology

    Reaching epidemic proportions, 1 in every 4 adults will have a stroke in their lifetime, with an estimated 14 million strokes occurring each year around the world. As a classical disease of aging, the incidence rate or risk of stroke doubles each decade after the age of 45. While approved thrombolytics have demonstrated modest effects at preventing disability, there are currently no treatments capable of reliably reversing pathology beyond the level of standard rehabilitation. Recent studies have demonstrated significant potential of regenerative growth factors in promoting neuroprotection and neurodegeneration in preclinical models of stroke. Remedium is developing a first-in-class treatment for ischemic stroke, which is not limited by the increased risk of hemorrhage, allowing for a broader therapeutic safety and efficacy window in the treatment of cerebral ischemia.

  • Rheumatology

    Affecting 1 in 7 adults, Osteoarthritis (OA) is the most prevalent rheumatic disorder characterized by cartilage loss and debilitating pain. As of today, there are no approved treatments capable of stopping or reversing disease progression with many patients requiring joint replacement. Remarkably, recent placebo-controlled clinical studies evaluating repeat intraarticular injection of FGF18 demonstrated the ability to regrow cartilage in arthritic knees, while potentially preventing progression to joint replacement surgery. This scientific breakthrough is limited by the need for frequent injections, with efficacy reversing upon discontinuation. Remedium is developing a novel FGF18 gene therapy, the only single-injection treatment potentially capable of reversing cartilage loss in OA.


Grounded in the Prometheus™ adjustable gene therapy platform, our pipeline consists of a broad range of regenerative therapeutics targeting diseases of aging and large clinical unmet needs. Each therapeutic candidate is developed by modularly applying proven fundamentals in novel ways, to treat well-characterized pathologies.


There is so much to life

The only worthy purpose is saving it!

Proven Fundamentals

Remedium therapies are based on proven fundamental components including clinically validated targets, commercial delivery vectors, and time-tested manufacturing technologies.

Novel Approach

The technology is then applied to treating disease using a fundamentally novel, patent pending approach. An approach, uniquely matched specifically with the target condition.

Infinite Potential

The Prometheus platform has truly infinite potential, enabling the replacement of a broad range of subcutaneously delivered biologics, with a single, adjustable-dose gene therapy.

Get In Touch

We are always interested in starting a new conversation and are looking forward to hearing from you. Thank you in advance for your inquiry and please have a wonderful day!

1116 Great Plain Ave, Suite 203                        
Needham, MA                        

P: +1 (978) 467 5217